Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Definitive radiation treatment of prostatic adenocarcinoma has been reported to produce good long-term local disease control, and distant disease failure is almost always associated with good local palliation. We examined late local complications in patients who died with recurrent prostate cancer after definitive radiotherapy as compared to patients treated with hormonal deprivation alone for advanced disease. Between 1979 and 1989 the tumor registry listed 33 men in whom definitive radiotherapy failed documented by bone scan or biopsy and 54 men who were managed with palliative hormonal therapy for noncurable disease. A complication was defined as a local problem requiring a procedure or hospitalization. Overall 23 of the radiotherapy cases (70%) had a local complication as compared to 16 of the patients (30%) who underwent only hormonal therapy. Local complications after radiotherapy included urethral stricture (10 cases), prostatic obstruction (8), hematuria (4), radiation cystitis (3), ureteral obstruction (2) and rectosigmoid radiation injury (4). Local complications after hormonal therapy consisted of prostatic obstruction (11 cases), ureteral obstruction (3) and hematuria (3). The radiotherapy group had 2 urinary and 2 fecal diversions, and the hormonal therapy group had none. In summary, we found a higher risk of late local complications in patients who had recurrence and died with metastatic prostate cancer after definitive radiotherapy, as compared to patients who only received hormonal therapy. These results question the belief that patients with distant disease in whom radiotherapy fails enjoy good long-term local palliation.
 ...
PMID:Late local complications after definitive radiotherapy for prostatic adenocarcinoma. 832 90

From January, 1986 to April, 1990, combination chemotherapy with ifosfamide (or cyclophosphamide), adriamycin, cis-platinum and peplomycin was performed in 15 patients with hormonally resistant metastatic adenocarcinoma. Three patients had partial response (PR) and 9 remained objectively stable (ST). The median response duration of PR + ST (12) was 5.7 months (range 2.8 to 18.0+). Three patients progressed while on this therapy. Of 8 patients with prior treatment of chemotherapy or chemo-hormonal therapy, 6 achieved an objective response (2 PR, 4 ST). Severe toxicities occurred in 2 patients. One died of lung fibrosis induced by peplomycin and the other received urinary diversion for persistent hemorrhagic cystitis. These results compare favorably with previous reports of chemotherapy treatment of metastatic prostatic cancer patients who failed on hormonal manipulation. However, careful treatment is needed for lung fibrosis and hemorrhagic cystitis.
 ...
PMID:[Combination chemotherapy with ifosfamide (or cyclophosphamide), adriamycin, cis-platinum and peplomycin (IAPP) for hormonally resistant metastatic prostatic cancer]. 172 41

Cyclophosphamide has been considered one of the reference drugs of chemotherapy in randomized trials in hormone-refractory prostate cancer by the National Prostatic Cancer Project (NPCP). Ifosfamide, another oxazaphosphorine agent, and an analog of cyclophosphamide, appears to be more active and less toxic in a broad spectrum of tumors. Fifteen patients with metastatic hormone-refractory prostate cancer were treated with continuous infusion of ifosfamide 2 g/m2 per day for 2 days, together with the uroepithelial protective agent Mesna 2.4 g/m2 per day for 2 days, both to be repeated every 3 weeks. All patients have failed on previous hormonal therapy and 7 patients had received previous chemotherapy. The median age was 66 years. Fourteen patients were evaluable; none of whom achieved an objective response. Four patients were stabilized and 10 had disease progression while on chemotherapy. Major toxicity included 2 reversible encephalopathy, 3 grade I reversible renal toxicity, and 1 hemorrhagic cystitis. We concluded that ifosfamide given in this schedule in this group of patients is not an active agent in prostate cancer.
 ...
PMID:Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer. 212 44

Therapy with proton beam is superior to that with photon beam in concentrating the dose within a lesion. Fifteen patients with urinary malignant tumors were treated by proton irradiation during the period from June, 1985 to March, 1989 at Particle Radiation Medical Center, University of Tsukuba. Four patients were with renal cell carcinoma, five with prostatic cancer and six with bladder cancer. Treatment results were assessed by change in tumor size either three or six months after the irradiation. In all the four cases with renal cell carcinoma, the tumor sizes were found to be unchanged without any enlargement. Of the five cases with prostatic cancer, two showed that the treatment was effective and the tumor sizes in the other three cases were found to be unchanged. In three of the six cases with bladder cancer the tumors disappeared while the treatment was found effective in two other and it did not cause any enlargement of the tumor in the remaining one. Although local control of the tumor was successful in all the cases, one patient with prostatic cancer and three with bladder cancer died of cancer. Various side effects, such as radiation cystitis, were observed. This prospective therapy is expected to replace the conventional photon therapy. However, some improvement is needed to make full use of the advantageous properties in dose distribution. Combination therapy with other general therapy is required for some cases.
 ...
PMID:[Clinical study of proton radiotherapy in urological cancers]. 215 15

Non-specific granulomatous prostatitis (NGP) is histologically defined and reported with an incidence below 3.4% in unselected series of patients. A survey of the literature concerning NGP is given on the basis of a retrospective investigation of 14 case-histories. Microscopically, NGP is characterized by focal or diffuse occurrence of granulomas in the prostate. The etiological significance has been attributed to acute non-specific prostatitis and local hypersensitivity and/or simple foreign-body reactions are considered to be pathogenetic factors. The mean age of patients suffering from NGP is stated to be 54-65 years. Clinically, NGP is poorly defined. Complaints of cystitis/urethritis within the last month and subsequently rapid development or aggravation of urinary obstruction are frequently reported on admission. On digital rectal examination the gland is enlarged, and carcinoma is often suspected. Fine-needle aspiration biopsy may be of some guidance. However, the diagnosis is settled postoperatively by histologic investigation, where prostatic cancer, iatrogenic granulomas and specific granulomatous inflammations must be considered as differential diagnoses. Irrespective the choice of treatment, conservative or surgery, the prognosis of NGP is excellent.
 ...
PMID:[Non-specific granulomatous prostatitis]. 264 32

We evaluated the results of urinary cytology, obtained from bladder washing, in the follow-up of patients with superficial bladder tumors. For the study, we used 545 samples. These were compared with the cystoscopic findings when cytology was negative, and with the biopsy findings when positive. We observed that the sensitivity of cytology increased with tumor grade, stage and number. The highest sensitivity rate was observed for carcinoma "in situ". However, a low specificity rate was observed for single, low grade/stage lesions. False-positives diminished inversely with cytologic grading, which was only 8% for cytology grade 3. There were more false-positives in patients that were on prophylactic therapy with thiotepa. The foregoing increased with the duration of treatment. Bladder lithiasis, abacterial cystitis, urinary infection, adenoma and prostatic cancer found to yield falsely positive results. False-negatives appeared principally in single, low grade/stage tumors. We underscore the low number of false-negatives observed in patients on thiotepa or those with bladder diverticulum. Follow-up of patients with true-negative or false-positive cytology showed a higher incidence and earlier tumor recurrence in the latter patient group. We discuss all the foregoing findings and present a protocol for patient follow-up.
 ...
PMID:[Cytology by lavage in the follow-up of bladder neoplasms]. 281 82

We treated 65 patients with prostatic cancer confined clinically to the prostate or periprostatic area during an 8-year period. Seven patients had stage A2, 38 stage B and 20 stage C disease. All 65 patients underwent staging pelvic lymphadenectomy and implantation of gold grains into the prostate (mean dose 3,167 rad). A total of 64 patients then completed a course of external beam irradiation to a mean total tumor dose of 6,965 rad. Complications of therapy were mild and limited (less than 3 months in duration) in most patients, and they included radiation cystitis (32 per cent), diarrhea (31 per cent), extremity lymphedema (7.7 per cent) and wound infection (3 per cent). Two patients suffered urinary incontinence after therapy and 2 (3 per cent) had diarrhea more than 3 months in duration. The actuarial 5-year survival rate for all patients was 87 per cent and the 5-year survival free of disease was 72 per cent.
 ...
PMID:Interstitial gold and external beam irradiation for prostate cancer. 312 84

Fifty nine patients with prostatic cancer treated by definitive external irradiation were retrospectively evaluated. The true pelvis and prostate gland were irradiated by a split course technique for 48-50 Gy and 68-70 Gy in 7 weeks with a booster dose of 20 Gy delivered in the rest period (after 24-26 Gy) to the prostate via small ports. The overall 3 and 5 year actuarial survival was 83% and 75%, respectively. Only four patients had persistent local disease and two of these (Stage D) died with local disease and distant metastases. Acute mild diarrhea or mild cystitis occurred in 26 patients whereas two patients developed chronic diarrhea lasting for 2 and 12 months after therapy. There were no long-term complications requiring interventional surgery. Sexual potency did not seem to be affected. These results indicate that carefully performed external radiotherapy with a booster dose delivered half-way through whole pelvic radiation is very well tolerated without affecting the local control rate.
 ...
PMID:Split course pelvic irradiation and a boost for carcinoma of the prostate. 370 93

Urinary arylsulfatase A activity expressed as units/mg of urinary creatinine was significantly increased in bladder cancer patients, but not in patients with other genitourinary tract disorders, such as cystitis, urethritis and prostatic cancer, nor in patients with non-urological malignant diseases. The urinary enzyme activity was positively correlated with the stage of the bladder cancer, while post surgical follow-up revealed a marked decrease of the activity. Arylsulfatase A activity was also shown to be higher in malignant than in normal bladder tissue, demonstrating the activity to be a function of the grade of the tumor. Furthermore, the isoelectric point (pI 5.2-5.3) of the tissue enzyme in the bladder tumor coincided with that of the urine enzyme from the same cancer patients; the pI of the enzyme in urine from normal subjects was 4.7. These results suggest that most of the urinary arylsulfatase A in bladder cancer originates from tumor tissue.
 ...
PMID:Arylsulfatase A activities in urine and tissues taken from bladder cancer patients. 615 61

We report a patient with prostate cancer who suffered from severe radiation cystitis after combined interstitial radiation with 125-Iodine-Seeds and external radiation (2000 rad). This patient was treated very successfully with intramural injection of Orgotein (Peroxinorm) into the bladder wall. Besides discussion of the aetiology of radiation cystitis we report our first favourable results with local and systemic treatment with Orgotein (Peroxinorm).
 ...
PMID:[Therapy of acute radiation cystitis. A case report]. 653 19


1 2 3 4 5 6 Next >>